| | Cell type | Cell markers | Therapeutic effect |
| | BM-MSCs | CD105+, CD73+, CD90+, CD45−, CD34−, CD14−, CD11b−, CD79 alpha, CD19−, and HLA-DR− [37–39] | Promote cell proliferation, collagen synthesis, growth factor release, wound contraction, neovascularization, and cellular recruitment to wounds [41–46].
| | ADSCs | CD31−, CD34+/−, CD45−, CD90+, CD105−, and CD146− [47–50] | Increase cell proliferation, collagen synthesis, promote neovessel formation, and tissue remodeling [47, 51, 52]. | | EPCs | CD34+, VEGFR-2+, and CD133+ [29, 40] | Promote vascularization secrete proangiogenic growth factors and cytokines, and differentiate into endothelial cells [53–55].
| | BMNCs | hematopoietic progenitor cell markers: CD133+, CD117+, and CD34
MSCs markers and endothelial progenitor population: CD34+/−, CD133+, and VEGFR2+ [56, 57] | Secrete angiogenic growth factors decrease local inflammation, and promote vascularization differentiate into endothelial cells [58–63]. | | Fibrocytes | CD 34+, CD11b+, CD13+, MHC II+, CD86+, CD45+, collagen-1+, procollagen-1+, CD3−, CD4−, CD8−, CD19−, and CD25− [64, 65] | Increasing cell proliferation ECM deposition, wound contraction, and vascularization.
Secrete of growth factors and chemokines [65–70]. |
|
|
